Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology April 9, 2025 Ellen Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold et al. 23 citations
Mood dysfunction is highly prevalent in Parkinson's disease (PD), a main predictor of functional decline, and difficult to treat-novel interventions are critically needed. Psilocybin shows early promise for treating depression and anxiety, but its potential in PD is unknown, as safety concerns have excluded people with neurodegenerative disease from previous trials. In this open-label pilot...